Indaptus Therapeutics is trading 10.64% lower at $2.94; the specific reason for the September 29, 2026 decline remains unclear. - No clear company-specific announcement explaining the move was identified. - The approximately $24 million private placement involving 20,338,974 shares is prior news, not a new catalyst today. - Supplied market context shows no broad index move of more than 0.5% in the same direction, so broader-market sentiment does not clearly explain the decline.